Drug Trial Radar · NCT07069712
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jul 17, 2025
Primary completion
Nov 9, 2027
Study completion Jul 16, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Jul 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease.
Conditions
- Gastroesophageal Adenocarcinoma
Interventions
Sonesitatug VedotinDrug
Sonesitatug Vedotin will be administered as an IV infusion.
RilvegostomigDrug
Rilvegostomig will be administered as an IV infusion.
Trastuzumab Deruxtecan (T-DXd)Drug
T-DXd will be administered as an IV infusion.
CapecitabineDrug
Capecitabine (Fluoropyrimidine) will be administered orally as chemotherapy standard of care.
5-Fluorouracil (5-FU)Drug
5-FU (Fluoropyrimidine) will be administered as a continuous IV infusion as chemotherapy standard of care.
FLOT ChemotherapyDrug
FLOT (5-FU, leucovorin, oxaliplatin, and docetaxel) Chemotherapy will be administered as an IV infusion.
Calcium folinateDrug
Calcium folinate will be administered as an IV infusion as chemotherapy standard of care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs) and serious adverse events (SAEs)Time frame: Until sub-study completion, up to 38 months
- Percentage of participants with pathological complete response (pCR)Time frame: Until sub-study completion, up to 38 months
Locations
70 sites in 11 countries. Site status is shown where the registry gives one.
Research Site
Newark, Delaware · Recruiting
Research Site
Washington D.C., District of Columbia · Recruiting
Research Site
Fairway, Kansas · Recruiting
Research Site
North Shores, Michigan · Recruiting
Research Site
New York, New York · Withdrawn
Research Site
New York, New York · Completed
Research Site
Pittsburgh, Pennsylvania · Recruiting
Research Site
Toronto, Ontario, Canada · Withdrawn
Research Site
Montreal, Quebec, Canada · Recruiting
Research Site
Montreal, Quebec, Canada · Recruiting
Research Site
Beijing, China · Recruiting
Research Site
Changchun, China · Recruiting
Research Site
Changzhi, China · Recruiting
Research Site
Chengdu, China · Recruiting
Research Site
Chengdu, China · Recruiting
Research Site
Fuzhou, China · Not yet recruiting
Research Site
Hangzhou, China · Recruiting
Research Site
Hangzhou, China · Recruiting
Research Site
Kunming, China · Recruiting
Research Site
Qingdao, China · Recruiting
Research Site
Shanghai, China · Recruiting
Research Site
Shijiazhuang, China · Withdrawn
Research Site
Tbilisi, Georgia · Recruiting
Research Site
Tbilisi, Georgia · Recruiting
Research Site
Tbilisi, Georgia · Recruiting
Research Site
Tbilisi, Georgia · Recruiting
Research Site
Florence, Italy · Recruiting
Research Site
Milan, Italy · Recruiting
Research Site
Milan, Italy · Recruiting
Research Site
Milan, Italy · Recruiting
Research Site
Modena, Italy · Withdrawn
Research Site
Pisa, Italy · Recruiting
Research Site
Rozzano, Italy · Recruiting
Research Site
Udine, Italy · Not yet recruiting
Research Site
Vicenza, Italy · Recruiting
Research Site
Chūōku, Japan · Recruiting
Research Site
Fukuoka, Japan · Recruiting
Research Site
Hidaka-shi, Japan · Recruiting
Research Site
Kashiwa, Japan · Recruiting
Research Site
Kitaadachi-gun, Japan · Recruiting
Showing 40 of 70 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.